With 11.5% CAGR, Hemophilia Market Size to Reach US$ 20.1 Billion 2022-2027

According to the latest report by IMARC Group "Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The global hemophilia market reached a value of US$ 10.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.

Hemophilia is a bleeding disorder that occurs due to a lack of blood-clotting proteins. Its symptom includes excessive bleeding from cuts and injuries, large and deep bruises, pain, swelling and tightness in joints, blood in urine and stool, and unexplained irritability. It can be congenital or developed due to autoimmune conditions, cancer, multiple sclerosis, and drug reactions. At present, it is widely treated using replacement, gene, and immune tolerance induction therapy across the globe.

Request for a free sample copy of this report: https://www.imarcgroup.com/hemophilia-market/requestsample

Hemophilia Market Trends and Drivers:

The growing global population and increasing cases of genetic disorders represent one of the key factors positively influencing the market. In addition, the increasing accessibility of treatments and rising affordability of hemophilia treatment is propelling the market growth. Besides this, the rising popularity of replacement therapy, which offers the missing clotting factor to patients from an external source, is strengthening the market growth. Furthermore, government and non-government organizations in various countries are conducting programs to raise awareness about hemophilia treatment, which is creating a favorable market outlook. In line with this, increasing investments in research and development (R&D) activities for the application of gene therapy to children and those with pre-existing antibodies against the delivery vector are projected to stimulate market growth in the coming years.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Type:

Hemophilia A
Hemophilia B
Hemophilia C
Others

Breakup by Treatment:

On-Demand
Prophylaxis

Breakup by Therapy:

Replacement Therapy
ITI Therapy
Gene Therapy

Market Breakup by Region:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

Competitive Landscape with Key Player:

Baxter International Inc.
Bayer AG
BioMarin Pharmaceutical Inc.
CSL Behring (CSL Limited)
F. Hoffmann-La Roche AG
Grifols S.A.
Kedrion S.p.A.
Novo Nordisk A/S
Octapharma AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/hemophilia-market

Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Related Reports By IMARC Group

Newborn Screening Market: https://www.imarcgroup.com/newborn-screening-market

Peptide Therapeutics Market: https://www.imarcgroup.com/peptide-therapeutics-market

Sterilization Equipment Market: https://www.imarcgroup.com/sterilization-equipment-market

Organ Preservation Market: https://www.imarcgroup.com/organ-preservation-market

Blood Culture Test Market: https://www.imarcgroup.com/blood-culture-test-market

Ureteral Stents Market: https://www.imarcgroup.com/ureteral-stents-market

Corporate Wellness Market: https://www.imarcgroup.com/corporate-wellness-market

Inhalation Anesthesia Market: https://www.imarcgroup.com/inhalation-anesthesia-market

Contact US

IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA 
Website: https://www.imarcgroup.com/
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.